A study to predict the efficacy of Vedolizumab in induction and maintenance therapy in patients of ulcerative colitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200063027

Enrollment

Unknown

Registered

2022-08-28

Start date

2022-08-30

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Meet the diagnosis of ulcerative colitis; 2. Currently in the active stage of the disease, with moderate to severe activity; 3. Age >= 18 years old; 4. Receive VDZ treatment for the first time.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic or intolerant to VDZ and stop treatment; 2. Patients with active intestinal Clostridium difficile infection can receive VDZ treatment after treatment turns negative; 3. Have a history of intestinal surgery;

Design outcomes

Primary

Measure	Time frame
Clinical remission;Endoscopic remission;	—

Countries

China

Contacts

Public ContactXie Ying

Drum Tower Hospital Affiliated to Nanjing University School of Medicine

247373927@qq.com+86 13585195902

Outcome results